KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Free Cash Flow: 2009-2025

Historic Free Cash Flow for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Sep 2025 value amounting to $24.0 million.

  • Rigel Pharmaceuticals' Free Cash Flow rose 10.85% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.2 million, marking a year-over-year increase of 535.27%. This contributed to the annual value of $31.4 million for FY2024, which is 647.36% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Free Cash Flow stood at $24.0 million for Q3 2025, which was down 21.31% from $30.5 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Free Cash Flow's 5-year high stood at $54.8 million during Q2 2021, with a 5-year trough of -$25.9 million in Q1 2022.
  • For the 3-year period, Rigel Pharmaceuticals' Free Cash Flow averaged around $7.2 million, with its median value being $302,000 (2024).
  • Per our database at Business Quant, Rigel Pharmaceuticals' Free Cash Flow crashed by 441.24% in 2021 and then spiked by 10,011.59% in 2025.
  • Rigel Pharmaceuticals' Free Cash Flow (Quarterly) stood at -$19.1 million in 2021, then dropped by 15.30% to -$22.0 million in 2022, then spiked by 71.61% to -$6.2 million in 2023, then surged by 332.00% to $14.5 million in 2024, then climbed by 10.85% to $24.0 million in 2025.
  • Its Free Cash Flow was $24.0 million in Q3 2025, compared to $30.5 million in Q2 2025 and -$893,000 in Q1 2025.